Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bluebird bio Inc.

www.bluebirdbio.com

Latest From bluebird bio Inc.

Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.

Pricing Strategies Gene Therapy

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

Financing StartUps and SMEs

Market-Changing Launches Expected In 2020

We might only be halfway through 2019, but In Vivo is taking in the long view and exploring some of the market-altering new drugs on the horizon that are expected to win approval and experience first launches at the opening of the next decade.

Market Intelligence Launches

Finance Watch: BIO Report Shows Record VC Funding Across Geographies

Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • bluebird bio LLC
  • bluebird bio LLC
  • Genetix Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • bluebird bio Inc.
  • Senior Management
  • Nick Leschly, Pres. & CEO
    Chip Baird, CFO
    Philip Gregory, CSO
    David Davidson, MD, CMO
    Joanne Smith-Farrell, PhD, CBO
    Alison Finger, Chief Commercial Officer
  • Contact Info
  • bluebird bio Inc.
    Phone: (339) 499-9300
    60 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register